![Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d5d7c187-2f1d-4f07-a0dd-825d6633f582/gr1.jpg)
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology
![An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-019-1857-3/MediaObjects/13075_2019_1857_Fig1_HTML.png)
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text
![Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial | Trials | Full Text Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial | Trials | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13063-017-1964-x/MediaObjects/13063_2017_1964_Fig1_HTML.gif)
Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial | Trials | Full Text
![SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer - European Urology SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c242775c-0dc2-4bd8-b3b5-a076cc5b31c0/gr1_lrg.jpg)
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer - European Urology
![Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial) Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)](https://bmjopen.bmj.com/content/bmjopen/5/12/e009562/F1.large.jpg)
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)
![How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download](https://images.slideplayer.com/23/6590870/slides/slide_3.jpg)
How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download
![Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study - The Lancet Oncology Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f87ffc6b-12e9-4552-b542-3f5adb72970f/gr1.gif)
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study - The Lancet Oncology
![An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension | Clinical and Translational Allergy | Full An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension | Clinical and Translational Allergy | Full](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13601-017-0172-9/MediaObjects/13601_2017_172_Fig1_HTML.gif)
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension | Clinical and Translational Allergy | Full
![Randomized controlled trial and open-label extension study designs.... | Download Scientific Diagram Randomized controlled trial and open-label extension study designs.... | Download Scientific Diagram](https://www.researchgate.net/profile/Wendy-Komocsar/publication/265174624/figure/fig1/AS:267323823095810@1440746374062/Randomized-controlled-trial-and-open-label-extension-study-designs-aNonresponders-20.png)
Randomized controlled trial and open-label extension study designs.... | Download Scientific Diagram
![Helios Capital on Twitter: "$SAVA New wording on open-label study vs. 2 weeks ago. https://t.co/E5EAaHkKJf" / Twitter Helios Capital on Twitter: "$SAVA New wording on open-label study vs. 2 weeks ago. https://t.co/E5EAaHkKJf" / Twitter](https://pbs.twimg.com/media/E_8dQbAXoAAHmBr.png)
Helios Capital on Twitter: "$SAVA New wording on open-label study vs. 2 weeks ago. https://t.co/E5EAaHkKJf" / Twitter
![Design of the lurasidone open-label core and extension switch studies.*... | Download Scientific Diagram Design of the lurasidone open-label core and extension switch studies.*... | Download Scientific Diagram](https://www.researchgate.net/publication/303715017/figure/fig1/AS:560604952711171@1510670044939/Design-of-the-lurasidone-open-label-core-and-extension-switch-studies-144-of-the-235.png)
Design of the lurasidone open-label core and extension switch studies.*... | Download Scientific Diagram
![Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension | Neurology Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension | Neurology](https://n.neurology.org/content/neurology/96/4/e610/F2.large.jpg)
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension | Neurology
![An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP) – topic of research paper in Health sciences. Download scholarly article PDF and read for free An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP) – topic of research paper in Health sciences. Download scholarly article PDF and read for free](https://cyberleninka.org/viewer_images/792903/f/1.png)